Advantage Investment Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Advantage Investment Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$9K	Hold	200	–	–	0.01%	670
2019 Q2	$11K	Hold	200	–	–	0.01%	645
2019 Q1	$11K	Hold	200	–	–	0.01%	630
2018 Q4	$9K	Hold	200	–	–	0.01%	681
2018 Q3	$12K	Hold	200	–	–	0.01%	674
2018 Q2	$11K	Hold	200	–	–	0.01%	635
2018 Q1	$10K	Hold	200	–	–	﹤0.01%	680
2017 Q4	$9K	Hold	200	–	–	﹤0.01%	713
2017 Q3	$10K	Hold	200	–	–	﹤0.01%	691
2017 Q2	$9K	Hold	200	–	–	﹤0.01%	726
2017 Q1	$8K	Hold	200	–	–	﹤0.01%	729
2016 Q4	$8K	Hold	200	–	–	﹤0.01%	677
2016 Q3	$8K	Hold	200	–	–	﹤0.01%	660
2016 Q2	$7K	Hold	200	–	–	﹤0.01%	653
2016 Q1	$8K	Buy	200 +100	+100%	+$3.88K	﹤0.01%	602
2015 Q4	$5K	Hold	100	–	–	﹤0.01%	688
2015 Q3	$5K	Hold	100	–	–	﹤0.01%	661
2015 Q2	$6K	Hold	100	–	–	﹤0.01%	675
2015 Q1	$6K	Buy	+100	New	+$5.41K	﹤0.01%	668

Other funds holding PBE

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

Advantage Investment Management's PBE Position: Q3 2019 in Review

Advantage Investment Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2019 at 200 shares worth $9K. The position accounts for 0.01% of the portfolio, ranked #670.

Advantage Investment Management first reported a position in PBE in Q1 2015 and has held it in 19 quarters since. The position peaked at $12K in Q3 2018. 73 funds tracked by Wall St. Rank hold PBE as of Q3 2019.

Advantage Investment Management held 200 shares of Invesco Biotechnology & Genome ETF worth $9K as of Q3 2019.
Advantage Investment Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2019.
Invesco Biotechnology & Genome ETF made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #670 holding.
Advantage Investment Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2015 and has held it in 19 quarters since.
Advantage Investment Management's Invesco Biotechnology & Genome ETF position peaked at $12K in Q3 2018.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.